| Literature DB >> 35897017 |
Zegui Huang1,2, Xiong Ding3, Qing Yue4, Xianxuan Wang1,2, Zekai Chen5, Zefeng Cai2, Weijian Li1,2, Zhiwei Cai1,2, Guanzhi Chen6, Yulong Lan2, Weiqiang Wu2, Shouling Wu7, Youren Chen8.
Abstract
BACKGROUND: It has been suggested that the baseline triglyceride-glucose (TyG) index, a simple surrogate measure for insulin resistance, is significantly associated with the occurrence of stroke. Nevertheless, the impact of longitudinal patterns of TyG on the stroke risk in hypertensive patients is still unknown. Hence, this study aimed to investigate the association between TyG index trajectory and stroke risk among hypertensive patients.Entities:
Keywords: Hypertension; Insulin resistance; Stroke; Trajectory; Triglyceride-glucose index
Mesh:
Substances:
Year: 2022 PMID: 35897017 PMCID: PMC9331781 DOI: 10.1186/s12933-022-01577-7
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 8.949
Baseline characteristics of 19924 hypertensive patients according to the trajectories of TyG index from 2006 to 2010
| Variables | Low-Stable | Moderate low-stable | Moderate high-stable | Elevated-stable | Elevated-increasing | P |
|---|---|---|---|---|---|---|
| N | 2483 | 9666 | 5759 | 1741 | 275 | – |
| Age, years | 59.38 ± 11.35 | 57.29 ± 11.35 | 55.76 ± 10.71 | 54.49 ± 10.13 | 51.88 ± 9.29 | < 0.01 |
| Male n (%) | 2029 (81.72) | 7886 (81.58) | 4708 (81.75) | 1478 (84.89) | 241 (87.64) | < 0.01 |
| Heart rate, beats/min | 72.72 ± 10.62 | 73.97 ± 10.91 | 75.51 ± 11.29 | 77.89 ± 11.77 | 78.69 ± 10.54 | < 0.01 |
| BMI, kg/m2 | 24.31 ± 3.27 | 25.61 ± 3.33 | 26.68 ± 3.31 | 26.99 ± 3.29 | 27.01 ± 3.30 | < 0.01 |
| SBP, mmHg | 140.83 ± 19.51 | 140.69 ± 19.11 | 142.21 ± 18.73 | 143.69 ± 19.16 | 142.43 ± 17.13 | < 0.01 |
| DBP, mmHg | 87.89 ± 10.71 | 88.89 ± 10.71 | 90.09 ± 10.68 | 90.93 ± 11.11 | 91.65 ± 10.38 | < 0.01 |
| Total cholesterol, mmol/L | 4.67 ± 0.87 | 4.95 ± 0.92 | 5.23 ± 1.03 | 5.43 ± 1.17 | 6.44 ± 1.79 | < 0.01 |
| hs-CRP, mmol/L | 1.26 (0.62, 3.01) | 1.04 (0.40, 2.60) | 1.30 (0.50, 3.10) | 1.60 (0.70, 3.70) | 1.61 (0.90, 3.72) | < 0.01 |
| TyG in 2006 | 7.94 ± 0.34 | 8.55 ± 0.37 | 9.22 ± 0.44 | 9.84 ± 0.52 | 10.45 ± 0.60 | < 0.01 |
| TyG in 2008 | 7.91 ± 0.32 | 8.56 ± 0.36 | 9.15 ± 0.42 | 9.87 ± 0.53 | 10.67 ± 0.63 | < 0.01 |
| TyG in 2010 | 7.97 ± 0.32 | 8.53 ± 0.38 | 9.13 ± 0.44 | 9.81 ± 0.49 | 10.86 ± 0.61 | < 0.01 |
| Current smoker, n (%) | 800 (32.22) | 3416 (35.34) | 2251 (39.09) | 794 (45.61) | 136 (49.45) | < 0.01 |
| Current drinker, n (%) | 698 (28.11) | 2983 (30.86) | 2126 (36.92) | 761 (43.71) | 134 (48.73) | < 0.01 |
| Active physical activity, n (%) | 415 (16.71) | 1573 (16.27) | 865 (15.02) | 230 (13.21) | 42 (15.27) | < 0.01 |
| Senior high school or above, n (%) | 351 (14.14) | 1865 (19.29) | 1240 (21.53) | 376 (21.60) | 64 (23.27) | < 0.01 |
| Atrial fibrillation, n (%) | 33 (1.33) | 90 (0.93) | 43 (0.75) | 10 (0.57) | 0 (0.00) | 0.02 |
| Diabetes mellitus, n (%) | 47 (1.89) | 648 (6.70) | 1296 (22.50) | 793 (45.55) | 176 (64.01) | < 0.01 |
| Hypoglycemic drugs, n (%) | 19 (0.77) | 231 (2.39) | 482 (8.37) | 284 (16.31) | 65 (23.64) | < 0.01 |
| Anti-hypertensive drugs, n (%) | 449 (18.08) | 1969 (20.37) | 1487 (25.82) | 504 (28.95) | 103 (37.45) | < 0.01 |
| Lipid-lowering drugs, n (%) | 9 (0.36) | 82 (0.85) | 114 (1.98) | 53 (3.04) | 13 (4.73) | < 0.01 |
TyG triglyceride-glucose index, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, hs-CRP high-sensitivity C-reactive protein
Fig. 1Triglyceride-glucose index trajectory in hypertensive patients during 2006–2010
Fig. 2Kaplan–Meier curves of incidence of outcomes according to TyG index trajectory. a Stroke; b Ischemic stroke; c Hemorrhage stroke
The hazard ratio (HR) of stroke and its subgroup in hypertensive patients according to trajectories of TyG from 2006 to 2010
| Low-Stable | Moderate low-stable | Moderate high-stable | Elevated-stable | Elevated-increasing | |
|---|---|---|---|---|---|
| Stroke | |||||
| Case/Total | 149/2483 | 715/9666 | 460/5759 | 159/1741 | 36/275 |
| IR | 6.52 | 7.97 | 8.62 | 9.91 | 14.67 |
| Model 1 | 1 (reference) | 1.33 (1.11, 1.58) | 1.53 (1.27, 1.85) | 1.84 (1.47, 2.31) | 2.97 (2.06, 4.29) |
| Model 2 | 1 (reference) | 1.27 (1.07, 1.53) | 1.35 (1.11, 1.64) | 1.44 (1.12, 1.84) | 2.24 (1.51, 3.32) |
| Model 3 | 1 (reference) | 1.26 (1.06, 1.52) | 1.35 (1.10, 1.64) | 1.43 (1.13, 1.83) | 2.21 (1.49, 3.28) |
| Ischemic stroke | |||||
| Case/Total | 127/2483 | 628/9666 | 417/5759 | 147/1741 | 32/275 |
| IR | 5.54 | 6.98 | 7.79 | 9.13 | 12.95 |
| Model 1 | 1 (reference) | 1.37 (1.13, 1.66) | 1.64 (1.34, 2.01) | 2.01 (1.58, 2.55) | 3.11 (2.10, 4.60) |
| Model 2 | 1 (reference) | 1.31 (1.07, 1.58) | 1.41 (1.14, 1.74) | 1.52 (1.17, 1.97) | 2.20 (1.45, 3.34) |
| Model 3 | 1 (reference) | 1.30 (1.07, 1.57) | 1.40 (1.13, 1.73) | 1.51 (1.16, 1.95) | 2.16 (1.42, 3.29) |
| Hemorrhagic stroke | |||||
| Case/Total | 32/2483 | 106/9666 | 54/5759 | 19/1741 | 4/275 |
| IR | 1.37 | 1.15 | 0.98 | 1.14 | 1.52 |
| Model 1 | 1 (reference) | 0.89 (0.60, 1.32) | 0.79 (0.51, 1.24) | 0.96 (0.54, 1.70) | 1.37 (0.48, 3.89) |
| Model 2 | 1 (reference) | 0.92 (0.62, 1.39) | 0.84 (0.52, 1.36) | 0.99 (0.53, 1.86) | 1.71 (0.56, 5.19) |
| Model 3 | 1 (reference) | 0.94 (0.63, 1.40) | 0.86 (0.54, 1.38) | 1.02 (0.55, 1.90) | 1.77 (0.58, 5.37) |
TyG triglyceride-glucose index, IR incidence rate (per 1000 person-years); Model: 1 adjusted for age, sex; Model 2: adjusted for heart rate, BMI, SBP, DBP, total cholesterol, hs-CRP, current smoker, current drinker, physical activity, education level, diabetes mellitus and atrial fibrillation on the basis of model 1; Model 3: included variables in model 2 and further adjusted for hypoglycemic drugs, anti-hypertensive drugs and lipid-lowering drugs
Subgroup analyses: the hazard ratio (HR) of stroke in hypertensive patients according to trajectories of TyG From 2006 to 2010
| Low-Stable | Moderate low-stable | Moderate high-stable | Elevated-stable | Elevated-increasing | P for interaction | |
|---|---|---|---|---|---|---|
| Sex | 0.06 | |||||
| Male | ||||||
| Case/Total | 125/2029 | 632/7886 | 402/4708 | 134/1478 | 31/241 | |
| 1 (reference) | 1.37 (1.13, 1.67) | 1.46 (1.18, 1.81) | 1.47 (1.12, 1.92) | 2.25 (1.46, 3.44) | ||
| Female | ||||||
| Case/Total | 24/454 | 83/1780 | 58/1051 | 25/263 | 5/34 | |
| 1 (reference) | 0.77 (0.48, 1.23) | 0.81 (0.48, 1.35) | 1.26 (0.67, 2.36) | 2.28 (0.82, 6.33) | ||
| Age | 0.80 | |||||
| Age < 60 y | ||||||
| Case/Total | 57/1346 | 359/5897 | 267/3860 | 103/1278 | 27/232 | |
| 1 (reference) | 1.38 (1.04, 1.83) | 1.40 (1.05, 1.91) | 1.42 (1.00, 1.98) | 2.01 (1.23,3 .29) | ||
| Age ≥ 60 y | ||||||
| Case/Total | 92/1137 | 356/3769 | 193/1899 | 56/463 | 9/43 | |
| 1 (reference) | 1.21 (0.96, 1.53) | 1.34 (1.02, 1.76) | 1.65 (1.14, 2.38) | 3.25 (1.58, 6.70) | ||
| BMI | 0.15 | |||||
| BMI < 28 | ||||||
| Case/Total | 128/2187 | 554/7604 | 305/3949 | 118/1148 | 19/174 | |
| 1 (reference) | 1.29 (1.06, 1.57) | 1.35 (1.08, 1.68) | 1.65 (1.26, 2.17) | 2.02 (1.20, 3.33) | ||
| BMI ≥ 28 | ||||||
| Case/Total | 21/296 | 161/2062 | 155/1810 | 41/593 | 17/101 | |
| 1 (reference) | 1.12 (0.70, 1.80) | 1.21 (0.75, 1.95) | 0.95 (0.54, 1.67) | 2.47 (1.23, 4.97) | ||
| BP | 0.83 | |||||
| BP < 140/90 mmHg | ||||||
| Case/Total | 39/951 | 178/3484 | 109/1784 | 34/517 | 6/71 | |
| 1 (reference) | 1.21 (0.85, 1.72) | 1.34 (0.90, 1.98) | 1.28 (0.77,2.13) | 1.64 (0.65, 4.07) | ||
| BP ≥ 140/90 mmHg | ||||||
| Case/Total | 110/1532 | 537/6182 | 351/3975 | 125/1224 | 30/204 | |
| 1 (reference) | 1.27 (1.03, 1.57) | 1.32 (1.05, 1.65) | 1.47 (1.11, 1.94) | 2.42 (1.56, 3.75) |
TyG triglyceride-glucose index; Adjusted for age, sex, heart rate, BMI, SBP, DBP, total cholesterol, hs-CRP, current smoker, current drinker, physical activity, education level, diabetes mellitus, atrial fibrillation, hypoglycemic drugs, anti-hypertensive drugs and lipid-lowering drugs.